SHR-9803 for Injection Approved for Clinical Trials
March 12, 2026
Source: drugdu
40
On March 11, Hengrui Medicine (600276/01276) issued an announcement stating that the company recently received the "Drug Clinical Trial Approval Notice" for SHR-9803 for injection issued by the National Medical Products Administration, and will conduct clinical trials in the near future.
This drug is a Class 1 therapeutic biological product.It can activate anti-tumor immune activity, specifically bind to and eliminate regulatory T cells within tumors, while reducing the impact on peripheral Tregs, aiming to improve the safety and efficacy of tumor treatment.
To date, the cumulative R&D investment in SHR-9803 injection-related projects is approximately RMB 18.3 million (unaudited).
In the first three quarters of 2025, Hengrui Medicine achieved revenue of RMB 23.188 billion and net profit attributable to the parent company of RMB 5.751 billion.
https://finance.eastmoney.com/a/202603113668880571.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Invests 5 million yuan to participate in the establishment of an investment fund to expand into the biopharmaceutical field March 12, 2026
- Huadong Medicine’s clinical trial application for injectable HDM2024 drug has been approved by the US FDA March 12, 2026
- Its subsidiary’s Class 1 innovative drug TQB3205 has been approved for clinical trials, intended for the treatment of advanced malignant tumors. March 12, 2026
- Novogene® has been approved, making its global debut in China! March 10, 2026
- CSPC indacaterol mometasone inhalation powder has been approved for clinical trials in China. March 10, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
